Your browser doesn't support javascript.
loading
Designed inorganic porous nanovector with controlled release and MRI features for safe administration of doxorubicin.
Näkki, Simo; Wang, Julie T-W; Wu, Jianwei; Fan, Li; Rantanen, Jimi; Nissinen, Tuomo; Kettunen, Mikko I; Backholm, Matilda; Ras, Robin H A; Al-Jamal, Khuloud T; Lehto, Vesa-Pekka; Xu, Wujun.
Afiliación
  • Näkki S; Department of Applied Physics, Faculty of Science and Forestry, University of Eastern Finland, Kuopio 70211, Finland; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London, London SE1 9NH, UK.
  • Wang JT; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London, London SE1 9NH, UK.
  • Wu J; Department of Pharmaceutical Analysis, School of Pharmacy, and The State Key Laboratory of Cancer Biology (CBSKL), The Fourth Military Medical University, Xi'an, Shaanxi 710032, China; Department of Oncology, Xijing Hospital, The Fourth Military Medical University, Xi'an, Shaanxi 710032, China.
  • Fan L; Department of Pharmaceutical Analysis, School of Pharmacy, and The State Key Laboratory of Cancer Biology (CBSKL), The Fourth Military Medical University, Xi'an, Shaanxi 710032, China. Electronic address: xxfanny@fmmu.edu.cn.
  • Rantanen J; Department of Applied Physics, Faculty of Science and Forestry, University of Eastern Finland, Kuopio 70211, Finland.
  • Nissinen T; Department of Applied Physics, Faculty of Science and Forestry, University of Eastern Finland, Kuopio 70211, Finland.
  • Kettunen MI; A. I. Virtanen Institute for Molecular Science, 70221 Kuopio, Finland.
  • Backholm M; Department of Applied Physics, School of Science, Aalto University, 02150 Espoo, Finland.
  • Ras RHA; Department of Applied Physics, School of Science, Aalto University, 02150 Espoo, Finland; Department of Bioproducts and Biosystems, School of Chemical Engineering Aalto University, 02150 Espoo, Finland.
  • Al-Jamal KT; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London, London SE1 9NH, UK. Electronic address: khuloud.al-jamal@kcl.ac.uk.
  • Lehto VP; Department of Applied Physics, Faculty of Science and Forestry, University of Eastern Finland, Kuopio 70211, Finland.
  • Xu W; Department of Applied Physics, Faculty of Science and Forestry, University of Eastern Finland, Kuopio 70211, Finland. Electronic address: wujun.xu@uef.fi.
Int J Pharm ; 554: 327-336, 2019 Jan 10.
Article en En | MEDLINE | ID: mdl-30391665
ABSTRACT
The inability of traditional chemotherapeutics to reach cancer tissue reduces the treatment efficacy and leads to adverse effects. A multifunctional nanovector was developed consisting of porous silicon, superparamagnetic iron oxide, calcium carbonate, doxorubicin and polyethylene glycol. The particles integrate magnetic properties with the capacity to retain drug molecules inside the pore matrix at neutral pH to facilitate drug delivery to tumor tissues. The MRI applicability and pH controlled drug release were examined in vitro together with in-depth material characterization. The in vivo biodistribution and compound safety were verified using A549 lung cancer bearing mice before proceeding to therapeutic experiments using CT26 cancer implanted mice. Loading doxorubicin into the porous nanoparticle negated the adverse side effects encountered after intravenous administration highlighting the particles' excellent biocompatibility. Furthermore, the multifunctional nanovector induced 77% tumor reduction after intratumoral injection. The anti-tumor effect was comparable with that of free doxorubicin but with significantly alleviated unwanted effects. These results demonstrate that the developed porous silicon-based nanoparticles represent promising multifunctional drug delivery vectors for cancer monitoring and therapy.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Doxorrubicina / Sistemas de Liberación de Medicamentos / Excipientes / Antibióticos Antineoplásicos Límite: Animals / Humans / Male Idioma: En Revista: Int J Pharm Año: 2019 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Doxorrubicina / Sistemas de Liberación de Medicamentos / Excipientes / Antibióticos Antineoplásicos Límite: Animals / Humans / Male Idioma: En Revista: Int J Pharm Año: 2019 Tipo del documento: Article País de afiliación: Reino Unido